7 August 2015 - CADTH has received notices of pending submissions from AbbVie and AstraZeneca:

• Ombitasvir with paritaprevir and ritonavir for patients with genotype 4 hepatitis C virus infection
• Dapagliflizin propanediol monohydrate (Forxiga) for certain patients with type 2 diabetes mellitus

For information about the patient input process or for additional instructions, please see the patient input page of the CADTH website.

For more details, go to: https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr/patient-input/open-calls-for-patient-input/cdr-patient-input-submission?brand_name=TBC&generic_name=Ombitasvir/%20paritaprevir/%20ritonavir&indicator=Hepatitis%20C%2C%20chronic%20%28genotype%204%29